Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations

BACKGROUND: Identification of activated epidermal growth factor receptor (EGFR) mutations and application of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have greatly changed the therapeutic strategies of non-small-cell lung cancer (NSCLC). However, the long-term efficacy of EGFR-TKI therapy is limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fang, Diao, Xia-Yao, Zhang, Xiao, Shao, Qiong, Feng, Yan-Fen, An, Xin, Wang, Hai-Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397445/
https://www.ncbi.nlm.nih.gov/pubmed/30823937
http://dx.doi.org/10.1186/s40880-019-0354-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397445/
https://www.ncbi.nlm.nih.gov/pubmed/30823937
http://dx.doi.org/10.1186/s40880-019-0354-z

Ejemplares similares